SAREPTA THERAPEUTICS ($SRPT) posted quarterly earnings results for Q1 2026 on Wednesday, May 6th. The company reported earnings of $3.16 per share, beating estimates of $1.01 by $2.15. The company also reported revenue of $730,800,000, beating estimates of $483,637,845 by $247,162,155.
Stock price change since market close: -8.35%
You can see Quiver Quantitative's $SRPT stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
SAREPTA THERAPEUTICS Insider Trading Activity
SAREPTA THERAPEUTICS insiders have traded $SRPT stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $SRPT stock by insiders over the last 6 months:
- IAN MICHAEL ESTEPAN (Chief Operating Officer) sold 13,187 shares for an estimated $294,201
- STEPHEN MAYO sold 7,239 shares for an estimated $123,207
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
SAREPTA THERAPEUTICS Hedge Fund Activity
We have seen 171 institutional investors add shares of SAREPTA THERAPEUTICS stock to their portfolio, and 165 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AQR CAPITAL MANAGEMENT LLC added 6,390,860 shares (+454.6%) to their portfolio in Q4 2025, for an estimated $137,531,307
- RENAISSANCE TECHNOLOGIES LLC removed 1,490,600 shares (-56.2%) from their portfolio in Q4 2025, for an estimated $32,077,712
- STATE STREET CORP added 1,294,534 shares (+24.4%) to their portfolio in Q4 2025, for an estimated $27,858,371
- BLACKROCK, INC. added 1,083,408 shares (+8.2%) to their portfolio in Q4 2025, for an estimated $23,314,940
- BNP PARIBAS FINANCIAL MARKETS removed 1,053,562 shares (-59.1%) from their portfolio in Q4 2025, for an estimated $22,672,654
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 996,859 shares (-72.9%) from their portfolio in Q4 2025, for an estimated $21,452,405
- VANGUARD GROUP INC added 993,283 shares (+9.2%) to their portfolio in Q4 2025, for an estimated $21,375,450
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
SAREPTA THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $SRPT in the last several months. We have seen 1 firms issue buy ratings on the stock, and 2 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Underperform" rating on 03/26/2026
- HC Wainwright & Co. issued a "Sell" rating on 01/14/2026
- Wedbush issued a "Outperform" rating on 12/09/2025
To track analyst ratings and price targets for SAREPTA THERAPEUTICS, check out Quiver Quantitative's $SRPT forecast page.
SAREPTA THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $SRPT recently. We have seen 6 analysts offer price targets for $SRPT in the last 6 months, with a median target of $32.5.
Here are some recent targets:
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $5.0 on 04/16/2026
- Yigal Nochomovitz from Citigroup set a target price of $13.0 on 03/26/2026
- Kostas Biliouris from Oppenheimer set a target price of $37.0 on 03/19/2026
- Uy Ear from Mizuho set a target price of $31.0 on 03/13/2026
- Yanan Zhu from Wells Fargo set a target price of $38.0 on 02/27/2026
- Yun Zhong from Wedbush set a target price of $34.0 on 01/23/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
